Skip to main navigation Skip to search Skip to main content

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

  • Anirban P. Mitra
  • , Vikram M. Narayan
  • , Sharada Mokkapati
  • , Tanner Miest
  • , Stephen A. Boorjian
  • , Mehrdad Alemozaffar
  • , Badrinath R. Konety
  • , Neal D. Shore
  • , Leonard G. Gomella
  • , Ashish M. Kamat
  • , Trinity J. Bivalacqua
  • , Jeffrey S. Montgomery
  • , Seth P. Lerner
  • , J. Erik Busby
  • , Michael Poch
  • , Paul L. Crispen
  • , Gary D. Steinberg
  • , Anne K. Schuckman
  • , Tracy M. Downs
  • , Robert S. Svatek
    • Joseph Mashni, Brian R. Lane, Thomas J. Guzzo, Gennady Bratslavsky, Lawrence I. Karsh, Michael E. Woods, Gordon A. Brown, Daniel Canter, Adam Luchey, Yair Lotan, Tracey Krupski, Brant A. Inman, Michael B. Williams, Michael S. Cookson, Kirk A. Keegan, Gerald L. Andriole, Alexander I. Sankin, Alan Boyd, Michael A. O'Donnell, Richard Philipson, Seppo Ylä-Herttuala, David Sawutz, Nigel R. Parker, David J. McConkey, Colin P.N. Dinney

Research output: Contribution to journal › Article › peer-review

20   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non–muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial'. Together they form a unique fingerprint.
Sort by

Biochemistry, Genetics and Molecular Biology

Pharmacology, Toxicology and Pharmaceutical Science